Form D · Pharmaceuticals
Neurotez Inc.
Bridgewater, NJ · CIK 0001725567
Offering snapshot reported Apr 10, 2020 · SEC filing
- Reported sold
- Yet to sell Offering amount: $2M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 10, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $98K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-364723
Up to 4.9% of amount raised for a successful offering
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| LIVINGSTON SECURITIES, LLC | 147364 | LIVINGSTON SECURITIES, LLC · CRD 147364 |
Source: Form D, filed Apr 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Wesson Ashford | Executive |
| James Harris | Director, Executive |
| Thomas Humphries | Director |
| Jane Johnston | Executive |
| Jukka Karjalainen | Executive |
| Hamish Mc Arthur | Executive |
| Bob Oliver | Director |
| George Perry | Director, Executive |
| Nikolaos Tezapsidis | Director, Executive, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
991 Highway 22 Suite 200 A
Bridgewater, NJ, 08807
Bridgewater, NJ, 08807